# Viit Health

Extending Lives through Light and Intelligence 

## Elevator pitch
Viit Health develops computer vision technology for non-invasive health monitoring. We create integral consumer healthcare solutions comprised of portable electronic devices, Artificial Intelligence models, and user friendly software applications, which are used together to accurately identify different biomarkers –blood glucose levels, SpO2, heart rate, blood pressure, and more– and derive meaningful personalized prevention and wellness insights from the data. Our hardware uses advanced optical techniques such as Near Infrared Spectroscopy (NIR), Photoplethysmography (PPG), and Light Rotation (LR) to identify the spectral footprint of particular biochemical compounds in human tissue and volumetric variations of the blood. Such data is then analyzed by intelligent image processing algorithms that comprise Classical & Deep Learning models, which can determine the correct level of each biomarker. Finally, the results are displayed through user-friendly prevention applications that can also share personalized recommendations to increase overall wellness (for clinical and individual use).

- Canonical URL: https://wefunder.com/viit.health
- Entity ID: wefunder:company:91083
- Last updated: 2026-06-05T23:53:30Z
- Generated at: 2026-06-06T03:14:06Z

## Quick facts
- Non-invasive AI platform measures 4+ biomarkers 97% faster and 98% cheaper than traditional tools
- Proprietary patent-pending technology measures Glucose, Blood Pressure, SpO2, Heart Rate, and more
- Validated in 3,900+ patients through 5 Clinical Trials with clinical-grade accuracy for all markers
- Potential to predict 27+ diseases and 19+ complications, such as diabetes, hypertension and more
- Paid pilot in deployment (Nov 2026): 180 units, 20K+ people, 18 months, $3M in projected revenue
- $2.3M raised from leading private investors. $3M in R&D grants awarded to background dev company
- Backed by leading US family office, two VCs, hospitals, public institutions & distribution partners
- Startup World Cup finalist, Draper Founder & Softeq alumni, Hello Tomorrow DeepTech Pioneer

## Active fundraises
- wefunder:fundraise:138683: 4(a)(6) successful (USD)
- wefunder:fundraise:138682: 4(a)(6) successful (USD)
- wefunder:fundraise:81712: 4(a)(6) successful (USD)
- wefunder:fundraise:81713: 4(a)(6) successful (USD)
- wefunder:fundraise:48087: 4(a)(6) successful (USD)
- wefunder:fundraise:48088: 4(a)(6) successful (USD)

## Story
Viit Health is entering commercialization — and as we begin scaling, we’re giving the WeFunder community access to a private Pre-Series A opportunity with preferred terms and exciting special perks!Our mission is bold: reshape the future of healthcare by making prevention simple, personalized, and accessible — helping extend 1 million lives by 10 healthy years over the next decade.Viit has built a non-invasive health monitoring platform that combines a pocket-sized optical device, AI-powered analytics, and personalized insights. Using light instead of needles or consumables, Viit measures blood glucose, blood pressure, oxygen saturation, heart rate, and other key biomarkers in under 30 seconds.With fast, painless monitoring and real-time personalized insights, Viit is designed to help detect early signs of health risk before disease progresses — empowering people, clinicians, and organizations to act sooner and help people stay healthier for longer.Today’s healthcare system is not truly built around health — it is built around disease.Non-communicable diseases (NCDs) like hypertension, heart disease, diabetes, and other metabolic disorders account for over 70% of deaths globally — claiming more than 40 million lives each year. Often symptomless in early stages, conditions like high blood pressure — affecting more than 1.2 billion people worldwide — or glucose-related dysfunction — estimated to impact half the world’s population — progress silently until disease becomes unavoidable.These threats, driven by sedentary lifestyles, poor nutrition, chronic stress, and inequitable access to healthcare, can lead to heart attacks, strokes, kidney failure, and neurodegenerative conditions. The crisis isn’t just medical — it’s a failure of early detection and accessible prevention.Monitoring vital health markers like blood glucose, blood pressure, and oxygen saturation remains a slow, fragmented, and costly process—especially for those at risk of chronic disease. Individuals often need multiple separate devices, each requiring setup, calibration, and manual interpretation.Blood glucose tracking, for example, still relies on painful finger pricks or expensive continuous monitors that involve frequent sensor insertions—costing users up to $3,600 annually. For many, especially those already managing complications like neuropathy, these tools are not just uncomfortable—they are unsustainable. At the clinic level, conducting a full assessment of basic vitals can take up to 17 minutes and cost nearly $15 per patient. These inefficiencies not only drive up costs but discourage consistent monitoring, delay diagnosis, and ultimately make prevention inaccessible for millions.Viit Health uses light and AI to measure key health biomarkers in a fast, painless, and non-invasive way. In 30 seconds, our device can measure blood glucose, blood pressure, oxygen saturation, heart rate, and more — without finger pricks, consumables, or multiple devices.Traditional clinical measurements can take up to 17 minutes and cost more than $15 per patient. Viit can complete a measurement in seconds for as little as $0.20, reducing time by up to 97% and cost by up to 98%.Our proprietary, patent-pending technology combines multiple optical and sensing methods into a compact device, connected to AI-powered software for signal analysis, longitudinal tracking, and personalized insights. This integrated approach allows us to capture stronger physiological signals and deliver more accurate, actionable health insights than single-sensor or algorithm-first solutions.Instead of overwhelming users with too much data, Viit focuses on the insights that matter most. By combining high-quality signals, efficient hardware, and AI, we aim to make real-time health monitoring more accessible for individuals, clinics, companies, and public health programs.Over seven years of R&D and multiple generations of device innovation, Viit Health has refined its proprietary technology through extensive calibration, signal optimization, and clinical validation. Since 2018, we’ve collaborated with leading healthcare institutions in the U.S. and Mexico, deploying 5 clinical studies and validating our technology in over 3,900 individuals to date.With current results showing 3.4 BPM Mean Absolute Error (MAE) for heart rate, 0.9% MAE for SpO₂, 4.1 - 7.2 mmHg MAE for blood pressure, and 6.4 - 15.7 mg/dL MAE for blood glucose levels, we have closed the gap between non-invasive wellness monitoring and clinical-grade performance. Over the next 18 months, we will complete FDA regulatory approval as a Clinical Decision Support System (CDSS) aimed toward cardiometabolic risk observation.* Preliminary results in controlled clinical settings / 1) Mean Absolute Error / 2) Calculated against gold-standard references / 3) Latest preliminary results obtained through cross-sectional and OGTT clinical studies for a wide glycemic range (49 - 489 mg/dL).Our active clinical studies are in two of the largest hospitals in Mexico: Hospital General de México and Hospital Juárez de México.Prevention is the only sustainable way to reduce the burden of chronic disease. Yet today, large-scale screening remains slow, expensive, and fragmented, making it difficult for organizations to identify risk early and act before health problems become more serious.Viit Health is built for population-level clinical monitoring. Our Hardware & Software-as-a-Service model, starting at $550 per month, combines non-invasive measurement devices, monitoring software, healthy habits coaching, and clinical oversight into one scalable service. This enables employers, clinics, hospitals, public health programs, and institutional partners to monitor key cardiometabolic biomarkers across large groups over time.Rather than selling hardware alone, Viit delivers a complete monitoring platform that helps organizations track health trends, identify emerging risks, and support earlier preventive action. In parallel, we will also license our technology to strategic distribution partners, allowing Viit to scale through established commercial channels while expanding access to preventive health monitoring.By reducing the time, cost, and complexity of traditional screening, Viit makes prevention practical at scale.Viit Health is directly addressing a $780B+ global market opportunity driven by the shift toward personalized, preventive healthcare. With an initial focus on North and Latin America, we see a $338B total addressable market, a $119B serviceable available market, and a $2.97B near-term obtainable market based on targeted deployment for which there are already active conversations.More than 2 billion people are living with or at high risk of metabolic and cardiovascular conditions, often without consistent access to early detection or preventive monitoring. As existing tools remain inefficient, expensive, and hard to scale, Viit Health offers a timely alternative: accessible, non-invasive, real-time monitoring designed for everyday use and population-level impact.CROP marks Viit Health’s commercial activation.This November, we will launch a paid, multi-center Cardiometabolic Risk Observation Program (CROP) under the supervision of the Hospital General de México.Together with InBody and Daily Human, we are preparing to deploy 180 Viit Gen-4 units across corporate wellness initiatives, monitor 20,000+ people over 18 months, and generate approximately $3M in revenue.The program combines Viit’s fast, non-invasive biomarker monitoring with InBody’s body composition analysis and Daily Human’s AI-powered healthy habits coaching — creating a scalable model for prevention, early risk observation, and long-term behavior change.CROP is designed to show how Viit can bring prevention into real-world settings — helping organizations monitor cardiometabolic risk earlier, more frequently, and at scale.Leading health experts, scientists, and investors recognize the urgent need for better tools to detect and manage chronic disease risk. That’s why Viit Health has gained support from a growing network of partners — including top research institutions in Mexico and the U.S., global health investors, engineering firms, and entrepreneurship organizations. Together, we’re building one of the most promising breakthroughs in consumer health: a scalable, science-backed platform for prevention that’s ready for the real world.Viit Health is led by a rare combination of scientific expertise, financial acumen, and mission-driven entrepreneurship. Our team brings decades of experience across biotech, engineering, clinical research, and venture building — paired with a deep commitment to advancing public health through innovation. We’ve built and scaled startups, secured global partnerships, led cutting-edge research, and executed in both corporate and clinical environments. With a clear vision and a strong operational foundation, we’re committed to delivering measurable value for both our users and investors — while creating lasting impact in the fight against chronic disease.Following our initial CROP deployment and first commercial revenue, Viit Health plans to raise a $3M Series A to accelerate the next phase of growth.This round is expected to support regulatory execution, manufacturing scale-up, and preparation for broader commercial expansion. In January 2027, we will begin submissions with both the FDA and COFEPRIS as a Clinical Decision Support System (CDSS) for cardiometabolic risk observation, with approvals targeted by the end of 2027.As we move through the regulatory process, we also plan to expand CROP by 220 additional units by July 2027, strengthening our real-world dataset and commercial traction.By early 2028, Viit Health aims to begin broader expansion across the U.S. and Mexico, targeting pre-identified institutional channels for population-level monitoring. After 2028, we intend to expand across Latin America and add new biomarker capabilities such as oxidative stress, cholesterol, triglycerides, HbA1c, and other cardiometabolic markers.The world faces a growing health and economic crisis: non-communicable diseases account for the vast majority of deaths, despite being largely preventable. What’s missing isn’t treatment — it’s access to early detection and practical prevention. Viit Health’s mission is to change that. After years of research, validation, and strategic partnerships, we’re ready to scale a breakthrough solution that delivers real-time, non-invasive health monitoring to individuals, healthcare providers, and public systems alike — with a model built for meaningful impact and strong, sustainable profitability.This is a chance to be part of a global shift — toward smarter tools, healthier lives, and a more sustainable future.

## FAQ
1. **Very intriguing opportunity that I'm strongly considering pending answers to the following questions: 1. Could you share the specificity and sensitivity of Gluco 1.0 compared to existing "gold standard" diagnostics (which I assume are the puncture-based methods you referenced)...**
   - Dear Kenneth, Thanks for reaching out! It's a pleasure to meet you. 1 - As we move forward with validation protocols for Gluco 1.0, we've been improving our assertiveness and are currently working with a 10% error margin in lab tests, which we will work to improve further. Puncture glucometers currently have a ±20% error margin in glucose concentrations ≥75 mg/dl, since they must be compliant with ISO 15197:2003. 2 - To our knowledge, there are very few competitors developing similar devices ...
2. **Truly appreciate your detailed response, Luis! I just invested and wish you and the team all the best with the years ahead. :-)**
   - Thank you very much Kenneth! Welcome to the ViiT Health Team!
3. **Hello, I like your plan to place this device in large institutions. How much do estimate your activation & monthly fees will be for the 3 price levels you have? Will the device have an option for battery operation? How robust is the unit? Does it require scheduled maintena...**
   - Hi John, thanks for your interest, it's nice to meet you. 1. The activation price for each device at all levels will be $ 250 USD, and the monthly fees will vary according to the selected amount of glucose readings per month (subscription), which could average $30 USD for individual detection, $50 USD for clinical detection, and $100 USD for prevention (since it's thought to mainly be placed in mid-to-large companies for massive prevention campaigns). 2. Yes. Our current devices used for all ...
4. **How do you intend to make money? Current monitoring systems make money from lancets and test strips. What is the breakdown of your revenue model?**
   - Hi Robert. Nice to meet you and thanks for your interest. We look to make money by selling subscription plans for glucose readings which are aimed towards individuals, clinics/health institutions and prevention campaigns with mid-to-large sized companies. Each of the aforementioned channels constitute a revenue stream within our business model. All devices will cost $250 USD to purchase and activate (which could be covered by insurance companies). From then on, we will charge a monthly fee (o...
5. **Hello, I am very curious and interested ... I got few questions... 1) What's your patent that competitors can't copy ... 2) How good is your test results with respect to the traditional model (anything you folks did ) 3) Any comparison with the constant monitoring (poke) thing...**
   - Hello Murali. It's a pleasure. 1) Our technology is currently protected by Industrial Secret and we have not yet filed for a patent. We use Near Infrared Spectroscopy and Computer Vision technology, which enabled us to devise a new way to understand the information that results of shedding light of specific wavelength through live tissue, and isolate certain chemical components such as glucose, after training our AI algorithms to identify specific energy footprints. We may file for a patent l...

## Team
- Luis Fernando Gomez (CEO)
- Mayra Mora (CTO)
- Antonio Garcia (CSO)
- Victoria M. Merino (CRO)
- Felix Agakov (Artificial Intelligence)
- Adriana Monroy Guzmán (Clinical Research)
- Luis Gomez Sanchez (Government Relations)
- Lorena De La Maza (Medical Relations)
- Gerardo Rioseco (Finance)
- Sofia Alvarez (Administration)

## Recent posts
- Viit Health Enters Commercial Deployment (2026-05-20T15:00:00Z)
- How Viit Health Could Change Everyday Care (2025-12-02T19:02:23Z)
- Almost Funded in 6 Days! (2025-06-24T23:55:51Z)
- We Are Back! (2025-06-20T21:00:46Z)
- 🚨 Viit Health’s Crowdfunding Campaign Ends Tonight – Don’t Miss Out! 🚀 (2024-07-30T15:42:53Z)
- 🎬 The Final Act: Your Last Chance to Be Part of Viit's Healthcare and Wellness Revolution! 🚀 (2024-07-29T18:50:46Z)
- Olympic Finish 🥇🏆 (2024-07-28T22:04:54Z)
- 🚀 Viit's Next Big Leap: Bioviit 3.0 🚀 (2024-07-27T22:33:54Z)
- 🚨 Last Chance Alert! 🚨 (2024-07-26T18:27:37Z)
- Final Countdown: Last Chance to Join Our Wefunder Campaign! (2024-07-25T18:15:44Z)
- Thanks for your support! -6 days (2024-07-24T16:34:17Z)
- 7 days left! (2024-07-23T17:09:05Z)
- Final Stretch! (2024-07-22T21:17:15Z)
- Validated approach fueled by the community! (2024-07-18T01:29:11Z)
- Viit Health Partners with Mexico's Largest Public Hospital! (2024-07-11T23:47:37Z)

## Q&A
- Q: Fernando, In response to a prior question concerning your device being patented you provided the following respomse: "1) Our technology is currently protected by Industrial Secret and we have not yet filed for a patent. We use Near Infrared Spectroscopy and Computer Vision technology, which enabled us to devise a new way to understand the information that results of shedding light of specific wavelength through live tissue, and isolate certain chemical components such as glucose, after training our AI algorithms to identify specific energy footprints. We may file for a patent later on but it will depend on our technology protection strategy." As the managing partner of a venture fund, attorney and +25 year investor in med tech start-ups, VIIT Health has no investment value unless it has patented technology. Many of the largest medical device companies in the world manufacture glucometer monitors. Your industrial "secret" can quite easily be reverse engineered once the product hits the market and perhaps, even from your FDA submission. You stand no chance of surviving in this market, no matter how good your product is, unless your technology is protected from them.
  - A: Dear Theodore, Thank you for your comment. I just wanted to update this response. We have now filed our full patent application both in the US and internationally (U.S. patent application No. 19/088,717 and PCT application No. PCT/US25/21174), which followed a provisional patent application filed March of 2024. We now have strengthen out protection strategy besides our trade-secret protected proprietary data sets. Best, Luis Fernando
- Q: Very intriguing opportunity that I'm strongly considering pending answers to the following questions: 1. Could you share the specificity and sensitivity of Gluco 1.0 compared to existing "gold standard" diagnostics (which I assume are the puncture-based methods you referenced)? 2. To your knowledge, are they any competitors currently developing similar devices? How does their progress compare to yours? 3. What is your preferred exit strategy: acquisition, IPO, or something else? How likely do you think each is in the next ten years? 4. How did you come up with the valuation cap for this campaign?
  - A: Dear Kenneth, Thanks for reaching out! It's a pleasure to meet you. 1 - As we move forward with validation protocols for Gluco 1.0, we've been improving our assertiveness and are currently working with a 10% error margin in lab tests, which we will work to improve further. Puncture glucometers currently have a ±20% error margin in glucose concentrations ≥75 mg/dl, since they must be compliant with ISO 15197:2003. 2 - To our knowledge, there are very few competitors developing similar devices but none have received FDA approval and thus have no commercial devices. Furthermore, their approaches to non-invasive glucose monitoring are different since they use reflectance through laser-pulses, prediction with hybrid testing (pricking for customized calibration) and graphene sensors (nano technology for molecule detection). Our device works with light transmittance, which allows us to have a full footprint of the analyzed tissue in order to eventually measure other substances such as triglycerides or cholesterol. We are currently in validation protocols which are expected to end by mid 2022, afterwards we will proceed for COFEPRIS (Mexico) approval by late 2022, which will allow us to start selling our devices. We will later move towards FDA approval, and we expect to be one of the first (if not the first) truly non-invasive glucometer to receive it. 3 - Our preferred exit strategy is acquisition. We believe it may be faster and more likely than an IPO because international pharmaceutical companies may take a heavy interest in our early progress. Both of them are viable in the next 10 years. 4 - Our valuation CAP was calculated by multiplying our projected EBITDA for 2024 (our second commercial year) by a factor of 5.5. I hope that these answers have provided sufficient clarity and that you can join our efforts to make health monitoring more accessible, painless and effective. Very best, Luis Fernando Gómez CEO
- Q: Would you like a promo to our club, the Vegan Investing Club? Please choose a convenient time to discuss: Calendly.com/mark-perlmutter VeganInvestingClub.org
  - A: Hi Mark, I contacted you through LinkedIn. Best, Luis Fernando
- Q: Please put an image of your new design in use into the offering. I had to go through the video twice to figure out how it works (a finger in the hole, unless I still didn't get it right.) Thanks.
  - A: Hi Steve, We just posted an update with a few pictures of the new device in use. Will upload a few more soon. Very best, Luis Fernando
- Q: Hello! Do you still need more investors for this campaign? Contact me on this Email Robertorsiniinvestment@gmail.com
  - A: Hello, Thank you, we will contact you. Very best, Luis Fernando
- Q: Hello, I just watched your interview with Angels & Entrepreneurs network and you mentioned that this same technology could potentially be used in the future to measure cholesterol levels in blood. Could this tech eventually be used to detect every compound that is measured by today's standard blood tests? Thank you.
  - A: Hello Eric, it's a pleasure. We can indeed track down other biochemical analytes (substances) like cholesterol within the human body by using the same technology, however, there is a calibration process for each analyte that naturally takes time and testing. We will firstly be able to track down substances such as cholesterol, triglicerids and potentially even alcohol, but before we look into other compounds, we must first deploy a thorough revision and understand which will behave similarly under the same light wavelength. We will provide more information as we progress with our research. Very best, Luis Fernando
- Q: Just a sugggestion: Considering that you have funded to date with a very small number of investors, I believe you could supercharge your funding in this final round without significantly altering future profitability by offering a 100% lifetime discount on health monitoring across the board. I've invested twice now, but I would definitely responded quicker if that was the subject line in the update email!
  - A: Hey Steve. Thanks very much for your continued support and for pointing that out. We can't modify the perks after we launch, but I'll be sure to mention the investment perks in upcoming communications. Very best,
- Q: Hello ! can we get an update on the progress? registration ? sales? Regards Richard C
  - A: Hey Richard. I just shared an investor update a few days ago. Very best.
- Q: Hello, some of the pages on your form C appear to be blank. What is Pulse Ox? What is the blood glucose device you are looking to get approved in 2025 and how is it different than the Bioviit? When you say you hope to initially deploy Bioviit as a prevention device for NGOs, does that mean to screen for diabetes? What is the benefit of being able to measure all these different biomarkers? Thanks
  - A: Hello Felix, Thanks for reaching out. 1) I did not know about the Form C, I've contacted the WeFunder team to see that that problem gets fixed (it seems that some pages are not loading), rest assured we completed all the necessary steps to file our Form C. 2) Pulse Ox refers to Pulse Oximetry, it specifically refers to using pulsated light to identify Heart Rate and Oxygen Saturation (like we do with our device). 3) The device that we aim to get approved by 2025 will probably be the same device that will be launched as a wellness device by the end of this year (unless we carry out significant product iterations by then), the important part will be that our blood glucose results will have (by then) undergone all necessary validations to be considered medical grade results for diagnostics by the FDA. 4) Bioviit as a prevention device will present blood glucose results as colored ranges (e.g. very low, low, adequate, high, very high, et...) and it will be used to redirect individuals towards the appropriate care. 5) All these biomarkers provide correlations between each other in order to increase accuracy, and they also provide sufficient information for more sophisticated personalized wellness recommendations. Additionally, the can be used to estimate other novel biomarkers by using AI. Please let me know if you have any other questions. Very best, Luis Fernando Gomez
- Q: Hello, can you please post an update with a letter signed by the examiner from one of the 13 Clinical Trials. I along with other investors would like to verify that these studies did take place. For example, the letter should have how many participants were involved and on which dates this took place. Also actual proof of the Grants awarded by the Mexican National Council of Science and Technology. Right now lack of published research is a big red flag. I have already contacted VIIT about this and have not received any response.
  - A: Hello Noah, I have just posted an updated containing such information. Sorry for the late reply, we've been heavily focused in calibration activities for our new device over the past few weeks. Please let me know if there are any additional questions you may have. Very best, Luis Fernando
- Q: Fernando, I recall meeting you briefly at the Softeq Venture Studio Investor Demo Day in Aug 2022. Happy to see you on Wefunder again. I really like what you have put together in terms of tech stack and think this is certainly a problem worth solving. I have a few questions/requests: 1) The science is a bit opaque to me. I realize you still have no publications of your own, but can you point to some references on the basic science behind the principles of measurement and analytics you are leveraging here 2) can you describe at high level how you are using NIR here-your deck mentions transmittance-through what, the finger? Are you measuring the analytes in the sweat, in the skin, in the blood? Also with what are you using computer vision for? images of the skin on the finger/nails or is it for deriving measurements such as pulse for example? 3) Any revenue to date what is the financial state? can't see the annual report you are referencing on the updates section. 4) I don't find the device and subscription prices particularly cheap. Am I missing something? Are you assuming that most of the cost will be insurance reimbursable? Have you obtained advice from US insurance system experts that this will be possible.
  - A: Hello Hani, Hope all is well. I'm glad we got a chance to connect again in this space and thank you for the encouraging words. 1) Of course, here are a few scientific publications that speak more about the technology and how it can be implemented: https://www.nature.com/articles/s41598-022-05570-8 https://www.mdpi.com/1424-8220/23/6/3319 https://pubs.aip.org/aip/adv/article/8/3/035216/22707/Determination-of-NIR-informative-wavebands-for https://www.news-medical.net/health/Photoplethysmography-(PPG).aspx 2.1) We transmit pulsated Near Infrared light of 3 different wavelengths (with a particular frequency) through a finger (ideally the ring finger) over a specific period of time (10 - 15 seconds) to identify the spectral footprint of each individual (at a specific time) and the volumetric variations of the sample. It's important to note that the way we analyze the data is by comparing the intensity of the incident light versus the resulting light (after it has passed through the finger). 2.2) We measure analytes in the whole sample (blood & tissue). 2.3) We use computer vision to analyze calibration protocol data (known values of venous glucose vs spectral footprints identified with our device) and create AI models that can learn to identify the presence of glucose (and other analytes) in the sample, identify correlations with other physiological variables, and accurately predict the amount of glucose present in the body after each measurement. I can share more information about our specific process with investors or prospective investors under an NDA. 3) The annual report was only sent to investors from the previous round (and it's also available for investors of the current round). We're pre-revenue, however, we currently have requests for 150 units to be delivered by the end of this year, and we expect to have sold many more by then. 4) The cost of Bioviit represents a massive cost reduction from available measurement methods (annually) for both individuals and institutions. We have received advice from insurance experts, however, our device will initially be sold as a wellness device to be used mainly for prevention, which will not contemplate a reimbursable expense for our first customers, but will save them a lot of money in prevention and timely detection. Please let me know if you have any additional questions, I'll be happy to address them. Very best, Luis Fernando
- Q: Mr L Fernando wrote this on 23 Dec 2021: "We don't yet have published papers online, however, we have been compiling some technical papers from our clinical trials that will shortly be uploaded to our "updates" section. We will also update all of you when we publish our first paper. ". I have looked for them but have not found . I hope I was wrong. Surely 18 months is sufficiently long enough to do what you promised... that is not a good sign... you may disagree?
  - A: Hi P Barbonis, We haven’t published any papers since our last raise, this is because our technology is sensitive and we have decided to be strongly protective until we complete our patent application process, which is currently underway, and until we acquire FDA clearance for some of our measured biomarkers. There are several technical and medical institutions that support us, made public through our campaign page, who can gladly account for our technology and our Calibration and Validation Protocols. We almost won last year’s Startup WorldCup in Silicon Valley, we participated in a year long accelerator program with Softeq Venture Studio (+25 year engineering company that has provided solutions for several Fortune 500 companies), who not only invested in us, but with whom we have also been working on our new device), we recently carried out a successful clinical trial with the largest nutrition related health institution in Latin America, we have completed several successful technical Due Diligence processes with our lead investors, etc. We will eagerly update all our investors when we’re ready for scientific and medical publication, for now, we can share technical papers only to investors or prospective investors under NDA agreements. Best,
- Q: Hi Luis, Glad to see the company continuing to move forward and looks like you already raised significant funding in this round. Have you been sending regular investor updates since the previous crowd funding round in 2022? I did not receive any updates in the past 18 months, which makes it difficult for me to commit more funds at this time. Can you please commit to providing regular updates (quarterly is a good frequency) to investors moving forward? Also, can you confirm that the early bird terms just have the 20% discount in addition to the standard terms? It looks like the valuation cap is the same for early bird versus standard. Thank you. - Eric
  - A: Hello Eric, We uploaded the Annual Report (2022) at the end of last year, it's strange that many investors did not receive a notification or email. You can find the report under the "updates" section dated December 31st. Last year we were deep in product development for our new device and we participated in an accelerator program with Softeq Venture Studio while preparing for our current Seed Round, it was a bit difficult to prepare quarterly reports with substantial evident progress (other than the Annual Report). Rest assured that from now on we will be sending quarterly reports to all our investors. The early bird terms for this round are a 20% discount on top of the CAP ($16M vs $20M). Hopefully this clears out your questions. It would be fantastic if you can help us reach our fundraising goal! Very best, Luis Fernando
- Q: I like this but how do you know the light will not cause cancer later on? Also this does not look portable. Thanks!
  - A: Hello Luke, We are using certain wavelengths that do not affect the body or cause any harm. We will undergo a comprehensive revision through our FDA application, in such studies we will prove the safety of our product through clinical trials and also by contrasting our technology with previous approved technological developments that use Near Infrared, and are currently being used across multiple industries. Our commercial device will be smaller and we will have different sizes for different settings. Very best, Luis Fernando
- Q: What is the percent accuracy against finger prick home tests?
  - A: Dear Mory, There is an average error margin of ±20% for regular puncture glucometers, while we have achieved ≥90% assertiveness in clinical trials. Very best, Luis Fernando